NASDAQ:TENX Tenax Therapeutics (TENX) Stock Forecast, Price & News $0.30 +0.01 (+1.81%) (As of 12:27 PM ET) Add Compare Share Share Today's Range$0.30▼$0.3150-Day Range$0.28▼$0.4152-Week Range$0.25▼$4.30Volume29,310 shsAverage Volume1.85 million shsMarket Capitalization$7.26 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tenax Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,871.1% Upside$6.00 Price TargetShort InterestHealthy0.10% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.46) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.05 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Tenax Therapeutics has a forecasted upside of 1,871.1% from its current price of $0.30.Amount of Analyst CoverageTenax Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.10% of the outstanding shares of Tenax Therapeutics have been sold short.Short Interest Ratio / Days to CoverTenax Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenax Therapeutics has recently increased by 114.02%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTenax Therapeutics does not currently pay a dividend.Dividend GrowthTenax Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TENX. Previous Next 2.5 News and Social Media Coverage News SentimentTenax Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Tenax Therapeutics this week, compared to 0 articles on an average week.Search Interest5 people have searched for TENX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Tenax Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Tenax Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 1.67% of the stock of Tenax Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Tenax Therapeutics are expected to grow in the coming year, from ($0.46) to ($0.30) per share.Price to Book Value per Share RatioTenax Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tenax Therapeutics (NASDAQ:TENX) StockTenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.Read More TENX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TENX Stock News HeadlinesJuly 19, 2023 | finance.yahoo.comTenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)July 13, 2023 | finance.yahoo.comTENX - Tenax Therapeutics, Inc.September 27, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsMay 31, 2023 | tmcnet.comTenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering UseMay 31, 2023 | finance.yahoo.comTenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)May 22, 2023 | finance.yahoo.comTENX: Prioritizing LevosimendanApril 12, 2023 | finance.yahoo.comTenax Therapeutics Prioritizes Development Of TNX-103 For Heart FailureApril 12, 2023 | finance.yahoo.comTenax Therapeutics Provides 2023 Business UpdateSeptember 27, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsApril 5, 2023 | finance.yahoo.comTENX: Patents Guide the WayMarch 31, 2023 | seekingalpha.comTENX Tenax Therapeutics, Inc.March 22, 2023 | finance.yahoo.comTenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)March 8, 2023 | msn.comRoth MKM Initiates Coverage of Tenax Therapeutics (TENX) with Buy RecommendationMarch 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Tenax Therapeutics (TENX) and Day One Biopharmaceuticals (DAWN)February 17, 2023 | finance.yahoo.comAnalysts Are Optimistic We'll See A Profit From Tenax Therapeutics, Inc. (NASDAQ:TENX)February 15, 2023 | finance.yahoo.comTENX: New Funding Puts Wind in the SailsFebruary 7, 2023 | finance.yahoo.comTriangle pharma raising millions amid uncertain futureFebruary 3, 2023 | marketwatch.comTenax Therapeutics Down 20% After Offering Gets PricedFebruary 3, 2023 | msn.comTenax Therapeutics stock dips after pricing $15.6M securities offeringFebruary 3, 2023 | finance.yahoo.comTenax Therapeutics Announces Pricing of Approximately $15.6 Million Public OfferingFebruary 2, 2023 | marketwatch.comTenax Therapeutics Shares Rise 73%, Co. Gets Patent for Hypertension TreatmentFebruary 2, 2023 | finance.yahoo.comWhy Tenax Therapeutics Shares Are Gaining Today?February 2, 2023 | investorplace.comWhy Is Tenax Therapeutics (TENX) Stock Up 149% Today?February 1, 2023 | marketwatch.comTenax Shares Double After Hours, Co. Gets Patent for Use of IV Levosimendan in PH-HFpEFFebruary 1, 2023 | tmcnet.comTenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary HypertensionFebruary 1, 2023 | finance.yahoo.comTenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)January 25, 2023 | reuters.comTENX.OQ - | Stock Price & Latest News | ReutersSee More Headlines Receive TENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TENX Company Calendar Last Earnings11/16/2021Today9/27/2023Next Earnings (Estimated)9/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TENX CUSIPN/A CIK34956 Webwww.tenaxthera.com Phone919-855-2100Fax919-855-2133Employees7Year Founded1967Price Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+1,920.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,050,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-96.87% Return on Assets-85.20% Debt Debt-to-Equity RatioN/A Current Ratio17.04 Quick Ratio17.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book0.46Miscellaneous Outstanding Shares23,862,000Free Float23,385,000Market Cap$7.09 million OptionableNot Optionable Beta2.07 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Christopher T. Giordano (Age 48)CEO, Pres & Director Comp: $563.04kMr. Eliot M. Lurier CPA (Age 65)CPA, Interim Chief Financial Officer Comp: $221.7kDr. Stuart Rich M.D. (Age 73)Chairman of Scientific Advisory Board, Chief Medical Officer & Director Comp: $416kMs. Nancy J. M. HecoxExec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.Mr. Doug RandallExec. VP of Commercial & Bus. OperationsDr. Douglas HaySr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsExicureNASDAQ:XCURAileron TherapeuticsNASDAQ:ALRNBiophytisNASDAQ:BPTSApplied Molecular TransportNASDAQ:AMTIProcessa PharmaceuticalsNASDAQ:PCSAView All Competitors TENX Stock - Frequently Asked Questions Should I buy or sell Tenax Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TENX shares. View TENX analyst ratings or view top-rated stocks. What is Tenax Therapeutics' stock price forecast for 2023? 2 Wall Street analysts have issued 1 year price targets for Tenax Therapeutics' stock. Their TENX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,920.2% from the stock's current price. View analysts price targets for TENX or view top-rated stocks among Wall Street analysts. How have TENX shares performed in 2023? Tenax Therapeutics' stock was trading at $2.2280 at the start of the year. Since then, TENX shares have decreased by 86.7% and is now trading at $0.2970. View the best growth stocks for 2023 here. When is Tenax Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, September 28th 2023. View our TENX earnings forecast. How were Tenax Therapeutics' earnings last quarter? Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its quarterly earnings results on Tuesday, November, 16th. The specialty pharmaceutical company reported ($3.00) EPS for the quarter, missing the consensus estimate of ($2.60) by $0.40. When did Tenax Therapeutics' stock split? Tenax Therapeutics shares reverse split on Wednesday, January 4th 2023. The 1-20 reverse split was announced on Wednesday, January 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Tenax Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO). What is Tenax Therapeutics' stock symbol? Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX." How do I buy shares of Tenax Therapeutics? Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tenax Therapeutics' stock price today? One share of TENX stock can currently be purchased for approximately $0.30. How much money does Tenax Therapeutics make? Tenax Therapeutics (NASDAQ:TENX) has a market capitalization of $7.09 million. How can I contact Tenax Therapeutics? Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The official website for the company is www.tenaxthera.com. The specialty pharmaceutical company can be reached via phone at 919-855-2100, via email at jesse@sternir.com, or via fax at 919-855-2133. This page (NASDAQ:TENX) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.